50 research outputs found
III. — M. G. Lechartier
No full textIII. — M. G. Lechartier . In: Revue internationale de l'enseignement, tome 45, Janvier-Juin 1903. pp. 554-555
III. — M. G. Lechartier
No full textIII. — M. G. Lechartier . In: Revue internationale de l'enseignement, tome 45, Janvier-Juin 1903. pp. 554-555
M. Montuclard. Conscience religieuse et démocratie, La deuxième démocratie chrétienne en France, 1891-1902
No full textLechartier Jean-Jacques. M. Montuclard. Conscience religieuse et démocratie, La deuxième démocratie chrétienne en France, 1891-1902. In: Revue de l'histoire des religions, tome 170, n°2, 1966. pp. 216-217
A composite absorbable implant used to treat subchondral bone cysts in 38 horses
No full textBackground
In the last 30 years, several treatments have been proposed to treat subchondral cystic lesions (SCLs) but there have been no randomised studies to compare different methods and there is no consensus as to the optimal treatment.
Objectives
To evaluate a biocompatible absorbable implant for the treatment of SCLs in young horses in different anatomical locations.
Study design
Retrospective case series.
Methods
Horses with SCLs were treated with debridement through a trans‐cortical extra‐articular approach and an absorbable implant was inserted in the cavity. Clinical and radiographic follow‐up was recorded and follow up ranged from 28 to 46 months (mean 37 months). Racing records were reviewed.
Results
Thirty‐eight horses between 10 and 24 months of age were included in the study. In 36 of 38 horses treated, lameness resolved, and 77% average filling of the cyst was measured 120 days after surgery on radiographs. In two cases, surgical complications were recorded.
Main limitations
Information about the resorption of the implant is not available. Radiographs were performed in various hospitals or at farms or training stables, therefore, possible minor variations in technique and positioning occurred.
Conclusions
The extra‐articular approach to the SCLs followed by the insertion of the absorbable implant led to clinical and radiographic improvement of the SCLs at 120 days after surgery. This technique, feasible in different anatomical locations, may offer an alternative to treat SCLs in young horses
Surgical Management of Subchondral Cystic Lesions of the Medial Femoral Condyle with an Absorbable Implant
No full textA transcortical extra-articular approach to facilitate curettage, irrigation, and placement of an absorbable implant to treat subchondral cystic lesions of the medial femoral bone condyle may be a useful surgical treatment option to improve lameness as well as the radiographic appearance of subchondral cystic lesions
Les conditions du travail : en France / par M. Émile Bender,.... Aux États-Unis / par M. G. Lechartier. En Angleterre / par M. Villars ; préface de M. Raoul Péret,... ; quelques considérations de M. Walter Berry,... ; lettre de Lord Askwith
No full textAvec mode text
Design of the MEBT rebunchers for the SPIRAL 2 driver
No full textInternational audienceThe SPIRAL 2 project uses normal conducting rebunchers to accelerate high intensity beams of protons , deuterons and heavier ions. All cavities work at 88 Mhz , the beta is 0,04 and 3 rebunchers are located in the MEBT line, which accepts ions with A/q up to 6. The paper describes the RF design and the technological solutions proposed for an original 3 gap cavity , characterised by very large beam holes (60mm) and providing up to 120 kV of effective voltag
Refurbishment of the the DEE on a Cavity for a Compact Cyclotron
No full textInternational audienceThis project relates to the restoration of the copper electrode of a resonator at GANIL. It makes following important problems of corrosion of the copper pipes.• Refurbishment of the DEE of a cavity in cooper for a compact cyclotron• Thermal computation• Implementation• Manufacturing• Three axe control• RF qualifications• Commissionnin
Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosis
No full textClofazimine (CZM) is an antileprosy drug that was recently repurposed for treatment of multidrug-resistant tuberculosis. In Mycobacterium tuberculosis, CZM appears to act as a prodrug, which is reduced by NADH dehydrogenase (NDH-2), to release reactive oxygen species upon reoxidation by O-2. CZM presumably competes with menaquinone (MK-4), a key cofactor in the mycobacterial electron transfer chain, for its reduction by NDH-2. We studied the effect of MK-4 supplementation on the activity of CZM against M. tuberculosis and found direct competition between CZM and MK-4 for the cidal effect of CZM, against nonreplicating and actively growing bacteria, as MK-4 supplementation blocked the drug's activity against nonreplicating bacteria. We demonstrated that CZM, like bedaquiline, is synergistic in vitro with benzothiazinones such as 2-piperazino-benzothiazinone 169 (PBTZ169), and this synergy also occurs against nonreplicating bacteria. The synergy between CZM and PBTZ169 was lost in an MK-4-rich medium, indicating that MK-4 is the probable link between their activities. The efficacy of the dual combination of CZM and PBTZ169 was tested in vivo, where a great reduction in bacterial load was obtained in a murine model of chronic tuberculosis. Taken together, these data confirm the potential of CZM in association with PBTZ169 as the basis for a new regimen against drug-resistant strains of M. tuberculosis.UPCO
In Vitro Combination Studies of Benzothiazinone Lead Compound BTZ043 against Mycobacterium tuberculosis
No full textBenzothiazinones (BTZ) are a new class of drug candidates to combat tuberculosis that inhibit decaprenyl-phosphoribose epimerase (DprE1), an essential enzyme involved in arabinan biosynthesis. Using the checkerboard method and cell viability assays, we have studied the interaction profiles of BTZ043, the current lead compound, with several antituberculosis drugs or drug candidates against Mycobacterium tuberculosis strain H37Rv, namely, rifampin, isoniazid, ethambutol, TMC207, PA-824, moxifloxacin, meropenem with or without clavulanate, and SQ-109. No antagonism was found between BTZ043 and the tested compounds, and most of the interactions were purely additive. Data from two different approaches clearly indicate that BTZ043 acts synergistically with TMC207, with a fractional inhibitory concentration index of 0.5. TMC207 at a quarter of the MIC (20 ng/ml) used in combination with BTZ043 (1/4 MIC, 0.375 ng/ml) had a stronger bactericidal effect on M. tuberculosis than TMC207 alone at a concentration of 80 ng/ml. This synergy was not observed when the combination was tested on a BTZ-resistant M. tuberculosis mutant, suggesting that DprE1 inhibition is the basis for the interaction. This finding excludes the possibility of synergy occurring through an off-target mechanism. We therefore hypothesize that sub-MICs of BTZ043 weaken the bacterial cell wall and allow improved penetration of TMC207 to its target. Synergy between two new antimycobacterial compounds, such as TMC207 and BTZ043, with novel targets, offers an attractive foundation for a new tuberculosis regimen.UPCO
